- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07504848
Stroke Mobility and Caregiver Outcomes
The Effect of Mobility Level in Stroke Patients on Anxiety, Depression, and Caregiver Burden in Caregivers
This study was designed to determine the effect of functional mobility levels of stroke patients on caregiver burden, anxiety, and depression in their caregivers.
Study Overview
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Atakum
-
Samsun, Atakum, Turkey (Türkiye), 55270
- Ondokuz Mayis University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
This study includes adult individuals with a first-ever unilateral stroke and their primary caregivers. Stroke patients aged 18-75 years, at least 3 months post-stroke, with sufficient cognitive function (MMSE ≥24), and stable medical status are included. Caregivers are adults who have been living with the patient for at least one year and are the primary, non-professional caregivers.
Description
Inclusion Criteria:
-
Stroke Patients:
- Diagnosed with stroke according to WHO criteria (≥20% disability rate documented in Adult Disability Health Board Report)
- Having a family member or relative who provides care
- First-ever and unilateral stroke
- Willing to participate voluntarily
- Aged between 18-75 years
- Post-stroke duration longer than 3 months
- Stable vital signs
- Scoring ≥24 on the Standardized Mini-Mental State Examination (SMMT) or the -Modified Mini-Mental State Examination for Illiterate Individuals (MMSE-E)
- Able to understand and speak Turkish
-
Caregivers of Stroke Patients:
- Willing to participate in the study
- Living with the patient for at least 1 year
- Being the primary (main responsible) caregiver and not receiving paid professional caregiving services
- Aged 18 years or older
- Scoring ≥24 on the Standardized Mini-Mental State Examination (SMMT) or MMSE-E
Exclusion Criteria:
-
Stroke Patients:
- Presence of severe comorbid conditions
- Unwillingness to participate
- History of multiple strokes
- Bilateral hemiplegia
- Presence of major neurological, orthopedic, or rheumatologic disorders affecting the musculoskeletal system other than stroke
- Congenital anomalies or amputation causing disability
- Uncontrolled arrhythmia, uncontrolled hypertension, or unstable cardiac conditions
- Botulinum toxin injection within the last 6 months
- Inability to establish cooperation
- Presence of neglect, aphasia, or hemianopsia
-
Caregivers of Stroke Patients:
- Unwillingness to participate
- Living with the patient for less than 1 year
- Presence of mental retardation, dementia, or severe psychotic disorders
Study Plan
How is the study designed?
Design Details
- Observational Models: OTHER
- Time Perspectives: CROSS_SECTIONAL
Cohorts and Interventions
Group / Cohort |
|---|
|
Caregivers
|
|
Stroke Patients
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Brunnstrom Stages of Hemiplegic Recovery
Time Frame: Baseline
|
Baseline
|
|
|
Burden Interview
Time Frame: Baseline
|
Baseline
|
|
|
Timed Up and Go Test
Time Frame: Baseline
|
Baseline
|
|
|
Beck Depression Inventory
Time Frame: Baseline
|
The Beck Depression Inventory (BDI) is scored between 0 and 63, where 0 indicates minimal or no depressive symptoms and 63 reflects severe depression; increasing scores correspond to greater severity of depressive symptomatology. |
Baseline
|
|
Beck Anxiety Inventory
Time Frame: Baseline
|
Beck Anxiety Inventory (BAI) ranges from 0 to 63, with 0 indicating minimal anxiety and 63 indicating severe anxiety; higher scores represent increased severity of anxiety symptoms. |
Baseline
|
|
Rivermead Mobility Index
Time Frame: Baseline
|
The Rivermead Mobility Index (RMI) ranges from 0 to 15. 0 indicates severe dependence with inability to perform basic mobility tasks. 15 indicates full independence in all assessed mobility activities. As the score increases, it reflects a progressive improvement in functional mobility, with greater independence in activities such as transfers, walking, and balance. |
Baseline
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2025/105
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.